Brentuximab Vedotin and Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis
Blood Adv 2024 Mar 19;[EPub Ahead of Print], J Driessen, F de Wit, AF Herrera, PL Zinzani, AS LaCasce, PD Cole, CH Moskowitz, R García-Sanz, M Fuchs, H Mueller, P Borchmann, A Santoro, H Schöder, JM Zijlstra, BA Hutten, AJ Moskowitz, MJ KerstenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.